BioMaxima

BioMaxima Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of BioMaxima (BMX.WA) as of Oct 16, 2026 is 53.63. In the previous year, Cash Conversion Cycle (CCC) was 114.34 — a change of -53.09% (lower).

Cash Conversion Cycle

53.63

YoY

-53.09%

Last updated:

Cash Conversion Cycle (CCC) of BioMaxima is 2025 53.63 . Cash Conversion Cycle (CCC) of BioMaxima was 2024 114.34 . It decreases by -53.09% lower compared to the previous year.

The BioMaxima Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
345.54 PLN
Jan 1, 2019
336.92 PLN
Jan 1, 2020
63.15 PLN
Jan 1, 2021
69.99 PLN
Jan 1, 2022
36.49 PLN
Jan 1, 2023
127.25 PLN
Jan 1, 2024
114.34 PLN
Jan 1, 2025
53.63 PLN
The BioMaxima Cash Conversion Cycle history
YEARCash Conversion CycleYoY
53.63-53.09%
114.34-10.15%
127.25+248.71%
36.49-47.86%
69.99+10.83%
63.15-81.26%
336.92-2.49%
345.54+6.13%
325.57+104.32%
159.35-18.26%
194.94+36.73%
142.57—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioMaxima Stock analysis

What does BioMaxima do? BioMaxima SA is a company based in Lublin, Poland, operating within the Health Care sector, specifically in the Health Care industry. The company went public via an IPO on June 8, 2010, and is listed under the ticker BMX.WA with ISIN PLBIOMX00015. BioMaxima SA specializes in biotechnology and laboratory diagnostics, manufacturing and distributing reagents and equipment for laboratory diagnosis. The company produces in vitro diagnostic reagents and offers a range of products including diagnostic reagents and analyzers for clinical biochemistry, rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse, urine analysis systems, hematology analyzers and reagents, ion-selective analyzers and reagents, reagents and immunological analyzers for cardiac markers, glucometers, and analyzers for gasometric and critical blood parameters tests. BioMaxima SA supplies hospitals and laboratories across Poland, Lithuania, Latvia, Romania, and France. The company merged with its wholly owned subsidiary Cebo Sp z o o on March 20, 2014. The company's website is https://biomaxima.com/. BioMaxima is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioMaxima stock

Cash Conversion Cycle (CCC) of BioMaxima is 53.63 in 2025.

Cash Conversion Cycle (CCC) of BioMaxima changed from 114.34 to 53.63, representing a -53.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) BioMaxima since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s BioMaxima with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BioMaxima

All Key Metrics — BioMaxima